Ahmed M Soliman
Overview
Explore the profile of Ahmed M Soliman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
1872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdel-Dayem M, Al Dhafer H, Soliman A, Al Ansi A, El-Sonbati S, Ishag A, et al.
J Econ Entomol
. 2025 Mar;
PMID: 40037784
Climate change has a substantial impact on the quality and diversity of insect pests, which may have adverse ecological and economic effects. The family Chrysomelidae represents one of the most...
2.
Thaci D, Ohtsuki M, Maul J, Szegedi A, Luna P, Lynde C, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(2):381-394.
PMID: 39904971
Introduction: Risankizumab is approved for treating moderate-to-severe psoriasis. This interim analysis at 25 months evaluated the effectiveness of risankizumab compared with other approved biologics (OtherBios) among patients with moderate-to-severe psoriasis...
3.
Warren R, Pavlovsky L, Costanzo A, Bukhalo M, Korman N, Huang Y, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(2):477-481.
PMID: 39821856
No abstract available.
4.
Cestari T, Souza C, Azulay-Abulafia L, Romiti R, Carvalho A, Silva de Castro C, et al.
An Bras Dermatol
. 2024 Dec;
100(2):260-271.
PMID: 39648106
Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective:...
5.
Rieger C, Soliman A, Kaplia K, Ghosh N, Lopez A, Venkatesan S, et al.
Microbiol Spectr
. 2024 Nov;
:e0234124.
PMID: 39530700
Methicillin-resistant (MRSA) is the leading cause of wound infections, often progressing into serious invasive bloodstream infections. MRSA disproportionately affects Indigenous peoples in Canada with higher rates of skin and wound...
6.
Warren R, Pavlovsky L, Costanzo A, Bukhalo M, Korman N, Huang Y, et al.
Dermatol Ther (Heidelb)
. 2024 Nov;
14(12):3273-3290.
PMID: 39516454
Introduction: Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of...
7.
Ezzedine K, Soliman A, Camp H, Ladd M, Pokrzywinski R, Coyne K, et al.
JAMA Dermatol
. 2024 Oct;
161(1):39-46.
PMID: 39475960
Importance: Defining meaningful improvement using the Total Vitiligo Area Scoring Index (T-VASI) and the Facial VASI (F-VASI) aids interpretation of findings from clinical trials evaluating vitiligo treatments; however, clear and...
8.
Armstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B
Dermatol Ther (Heidelb)
. 2024 Oct;
14(11):3071-3081.
PMID: 39453596
Introduction: Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess...
9.
Amer M, Soliman A, Do T, Hegab A, El-Kelesh E, Li Y, et al.
J Vet Med Sci
. 2024 Oct;
86(11):1177-1184.
PMID: 39358244
In Egypt, camel trypanosomiasis is widespread. From October 2021 to March 2022, we collected 181 blood samples from apparently healthy one-humped camels (Camelus dromedarius) in Cairo and Giza Governates. The...
10.
Strober B, Soliman A, Li C, Patel M, Unigwe I, Gisondi P
J Am Acad Dermatol
. 2024 Aug;
91(6):1143-1149.
PMID: 39197499
Background: The relationship between biologic treatments for psoriasis (PsO) and the development of inflammatory arthritis in patients is not fully understood. Objective: The objective of this study was to analyze...